such as serum and urine. Samples of blood (centrifuged to obtain cell-free serum) and hemodialysate were simultaneously collected from selected patients at regular intervals during the entire 6-hour hemodialysis treatment. These samples were filtered through membranes to remove particulates and proteins and were then analyzed by use of a 60-cm zBondapak-C18 column, an aqueous sodium acetate/methanol gradient, and detection at 254 nm. The identification of components in the eluate was based on retention times, ultraviolet absorption spectra, and mass spectra. From the amounts of several metabolites in the various physiological fluid pools during hemodialysis, we concluded that they mostly originate from tissue fluids. We also observed that (1) , as is combined gas chromatography-mass spectrometry for identifying the excreted metabolites (2) .
The most widely-used means for providing symptomatic relief from uremia caused by renal failure is hemodialysis.
Other therapeutic treatments include peritoneal dialysis, the use of ingested sorbents, and kidney transplantation (3) (4) (5) We quantitated reasonably well-resolved peaks corresponding to known compounds by determining peak heights or peak areas and comparing these with working curves obtained for known compounds, as previously described (1) . In all cases studied, both peak heights and peak areas proved to be linearly related to concentrations over the ranges found. Figure  1 ) are identical. Other compounds Figure  2 . It can be seen that the absorption spectra of listed with Figure  1 whose identities have been so yenthe pure reference material and of the eluted component fled include creatinine, uracil, uric acid, hypoxanthine, 
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Ideatfty Structure and of peak 13 ( Figure  1 ), hippunic acid, have been confirmed by mass spectrometry. These results agree with previously published data reported for these two compounds (27, 28 Table 2 . Also included in Table  2 
1,6-Dihydro-1-methyl-6-oxonicotinamide (5-carbamovl-
1-methyl-2(
1H)-pyridone)
